Pfizer's Q4 2023 financial report: adjusted EPS beats estimates at $0.10, FY2023 EPS down 72%, Q4 sales decline 41% to $14.25B. CEO's positive outlook and reaffirmed 2024 guidance.

Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per ...

In short, Pfizer's future is going to look very different from -- and much better than -- its recent past. Its Q4 results don't matter much with that future in view. 10 stocks we like better than ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 billion, a 22% increase year over year. Comirnaty revenue declined by ...

Pfizer (PFE) is trading lower premarket on Tuesday after mixed Q4 results and an FY23 outlook which is seen lower than expected. Q4 Adjusted EPS grew +44% Y/Y to $1.14, beating ...

Releasing Q4 and FY 2023 earnings yesterday, Pfizer revealed that total revenues of $58.5bn in 2023 represented a 42% year-on-year drop, primarily thanks to its COVID franchise, with the vaccine ...

However, Pfizer easily beat what Wall Street analysts expected on the bottom line. The company announced Q4 adjusted diluted earnings per share (EPS) of $0.62, a 32% year-over-year jump.

Pfizer reported Q4 2024 revenue of $17.8 billion, with $13.7 billion from non-COVID products, reflecting 11% operational year-over-year growth. Key growth drivers included the Vyndaqel family ...

Pfizer projects full-year 2017 adjusted earnings per share of $2.50 to $2.60. That's in the ballpark of what Wall Street expects and reflects year-over-year growth of more than 6% at the midpoint ...

Analysts estimate adjusted EPS of $0.85 vs. $0.42 in Q4 FY 2020. Pfizer's revenue is expected to grow at a robust pace, but slower than Q3 FY 2021. The U.S. government has doubled its order for ...